| Fiscal Period | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Period End Date | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
| Total Liabilities Shareholders' Equity | 49,426.60 | 38,863.80 | 32,285.10 | 29,746.90 |
| Accumulated Depreciation Total | -9,202.90 | -9,258.70 | -8,522.00 | -7,919.80 |
| Cash Equivalents | 250.70 | 260.00 | 292.80 | 231.00 |
| Other Liabilities Total | 275.20 | 337.90 | 223.10 | 192.70 |
| Accrued Expenses | 3,041.00 | 2,971.10 | 2,801.90 | 2,403.60 |
| Long Term Debt | 380.00 | 380.00 | 0.00 | 380.00 |
| Common Stock Total | 83.40 | 83.40 | 83.30 | 83.20 |
| Other Equity Total | 189.10 | 196.90 | 162.70 | 276.40 |
| Other Current Assets Total | 294.60 | 241.00 | 449.80 | 351.10 |
| Prepaid Expenses | 188.30 | 194.70 | 145.20 | 113.80 |
| Total Assets | 49,426.60 | 38,863.80 | 32,285.10 | 29,746.90 |
| Current Portof LT Debt/ Capital Leases | 85.70 | 130.70 | 480.40 | 101.70 |
| Additional Paid- In Capital | 855.30 | 818.60 | 710.90 | 670.10 |
| Cash | 1,199.70 | 435.00 | 269.50 | 1,238.40 |
| Total Equity | 33,549.60 | 28,254.80 | 23,286.10 | 19,212.40 |
| Long Term Investments | 1,532.90 | 572.00 | 542.10 | 808.90 |
| Retained Earnings( Accumulated Deficit) | 32,648.20 | 27,255.00 | 22,456.10 | 18,342.80 |
| Treasury Stock- Common | -226.40 | -99.10 | -126.90 | -160.10 |
| Total Common Shares Outstanding | 83.20 | 83.26 | 83.08 | 82.98 |
| Property/ Plant/ Equipment Total- Gross | 18,900.70 | 16,858.40 | 15,151.40 | 14,086.30 |
| Tangible Book Valueper Share Common Eq | 271.10 | 288.35 | 236.72 | 192.39 |
| Goodwill Net | 1,313.90 | 550.10 | 547.40 | 547.30 |
| Total Liabilities | 15,877.00 | 10,609.00 | 8,999.00 | 10,534.50 |
| Total Debt | 4,676.60 | 2,002.00 | 1,347.20 | 3,384.50 |
| Short Term Investments | 4,325.50 | 7,436.30 | 5,601.90 | 2,951.30 |
| Cashand Short Term Investments | 5,775.90 | 8,131.30 | 6,164.20 | 4,420.70 |
| Total Receivables Net | 11,070.30 | 9,883.10 | 8,799.30 | 7,808.30 |
| Notes Payable/ Short Term Debt | 3,804.50 | 1,272.30 | 739.00 | 2,708.20 |
| Deferred Income Tax | 1,403.80 | 84.10 | 76.00 | 1.40 |
| Accounts Receivable- Trade Net | 9,042.00 | 8,029.80 | 7,248.50 | 6,676.40 |
| Property/ Plant/ Equipment Total- Net | 9,697.80 | 7,599.70 | 6,629.40 | 6,166.50 |
| Minority Interest | 377.80 | - | - | - |
| Total Current Liabilities | 13,033.80 | 9,588.00 | 8,572.10 | 9,765.80 |
| Total Inventory | 7,689.00 | 6,355.20 | 4,867.00 | 5,088.40 |
| Accounts Payable | 2,647.80 | 2,614.40 | 2,268.40 | 2,266.20 |
| Other Currentliabilities Total | 3,454.80 | 2,599.50 | 2,282.40 | 2,286.10 |
| Total Long Term Debt | 786.40 | 599.00 | 127.80 | 574.60 |
| Intangibles Net | 9,680.30 | 3,695.10 | 3,072.40 | 2,701.10 |
| Other Long Term Assets Total | 1,917.20 | 1,174.50 | 779.20 | 1,356.10 |
| Note Receivable- Long Term | 266.40 | 467.10 | 289.10 | 384.70 |
| period Length | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 25,018.10 | 24,805.30 | 20,425.50 | 17,782.30 |
| Capital Lease Obligations | 406.40 | 219.00 | 127.80 | 194.60 |
Dr Reddy's Laboratories Dividend Dr Reddy's Laboratories Bonus Dr Reddy's Laboratories News Dr Reddy's Laboratories AGM Dr Reddy's Laboratories Rights Dr Reddy's Laboratories Splits Dr Reddy's Laboratories Board Meetings Dr Reddy's Laboratories Key Metrics Dr Reddy's Laboratories Shareholdings Dr Reddy's Laboratories Profit Loss Dr Reddy's Laboratories Cashflow Dr Reddy's Laboratories Q1 Results Dr Reddy's Laboratories Q2 Results Dr Reddy's Laboratories Q3 Results Dr Reddy's Laboratories Q4 Results
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks